 |
|
|
|
 |
|
|
| Article 1 to 10 out of 72 concerning Novartis International AG
|
-
Antisoma's ASA404 programme to expand with new pivotal trial in lung cancer
(07/21/2008)
ATTRACT-2 study will evaluate ASA404 as second-line treatment
Antisoma plc ( announced that its Tumour-Vascular Disrupting Agent, ASA404, will enter a second pivotal phase III trial this year. The ATTRACT-2 (Anti-vascular Targeted Therapy: Researching ASA404 in Cancer Treatment-2) trial will be conducted by ...
-
New strategic partnership strengthens Lonza's position as leading supplier to the life science industry
(07/15/2008)
Strategic partnership concluded with Novartis for the joint development and manufacture of its biological pipeline
Novartis and Lonza have entered into a long term strategic partnership for the joint development and manufacture of the Novartis biological pipeline. Lonza will contribute its biotech leadership knowledge in process development and the manufacturing ...
-
Novartis completes acquisition of 25% stake in Alcon from Nestlé for approximately US$ 10.4 billion in cash
(07/09/2008)
First step toward majority ownership of the world leader in eye care
Novartis has acquired a 25% stake in Alcon Inc. as part of a definitive agreement with Nestlé S.A. reached in April 2008 that provides the right to acquire majority ownership of the world leader in eye care in two steps. The first step was ...
-
Intercell receives milestone payment triggered by initiation of further clinical trial for Flu vaccine with IC31
(06/16/2008)
Further clinical trial for a seasonal flu vaccine containing Intercell's adjuvant IC31 being initiated
Intercell AG announced progress in its collaboration with Novartis to develop an improved Influenza vaccine. Novartis now has initiated its in-house development program with clinical trials designed to demonstrate safety and immunogenicity of a ...
-
BTG plc: Acquisition of Protez Pharmaceuticals by Novartis
(06/09/2008)
BTG to receive approximately $5 million in respect of its shareholding in Protez upon close of transaction with further potential payments
BTG plc noted an announcement by Novartis that is to acquire Protez Pharmaceuticals, a company focused on the discovery and development of novel antibiotics that was founded in 2003 by BTG alongside Protez management members Chris Cashman, Dr Klauss ...
-
Novartis Menveo vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial
(05/07/2008)
First Phase III, head-to-head data show Menveo may offer greater protection for adolescents compared to Menactra
New Phase III data for Menveo® (MenACWY-CRM) show that the vaccine produced a greater immune response against meningococcal serogroups A, C, W-135 and Y in adolescents 11-18 years of age compared to Menactra®. Infection with any of these four ...
-
Antisoma announces start of phase III lung cancer trial of ASA404
(04/14/2008)
Initiation triggers USD 25 million milestone payment from Novartis
Antisoma plc announced that its partner Novartis has started the pivotal phase III trial of ASA404 combined with first-line chemotherapy in non-small cell lung cancer (NSCLC). The study, called ATTRACT-1, is designed to support applications for ...
-
ACZ885, a new biological drug in development, shows potential in treating serious life-long autoinflammatory diseases
(04/10/2008)
Human monoclonal antibody ACZ885 blocks interleukin 1ß, a key chemical messenger that causes inflammation and tissue destruction
New data demonstrate that ACZ885, a human monoclonal antibody in Phase III development, achieves long-lasting clinical remission in patients with genetic autoinflammatory diseases. The results indicate that ACZ885 could develop into a major ...
-
SPP100 (Tekturna/Rasilez) reduces left ventricular hypertrophy
(04/03/2008)
Latest study reveals further potential benefits of renin inhibitor in heart disease
Speedel welcomed promising results from the latest SPP100 (Tekturna/Rasilez) surrogate marker clinical trial which were announced by Novartis. The study results show that SPP100, the first-in-class direct renin inhibitor, has shown clinically ...
-
New Novartis Research Institute first to focus on innovative vaccines for the developing world
(02/26/2008)
Novartis announced the opening of a new research institute in Siena with a nonprofit mission to exclusively focus on the development of vaccines for diseases of the developing world. The NVGH's goal is to address the unmet medical need for vaccines ...
|
|
|
|
|
Top